|
|
Post by dreamboatcruise on Jun 6, 2018 10:58:14 GMT -5
That's a bit Apples and Oranges if you talking about a real change in script trajectory vs management and people on proboards talking about the aspiration of Afrezza becoming a "Standard of Care"... we are currently a blip in side thought as to the standard of care for diabetes in US. It will take a long time and a lot of work to change that. I'm sure you'll be reading here a LOT about SOC, but that is a "tell" only in it is people "telling" themselves their investment will pay off eventually. Hopefully we get some real evidence of a trajectory change and real sustained growth in NRx... or meeting the low end of revenue guidance will start slipping from the grasp of the possible. No inspirational talk of becoming SOC will change that. - I agree. I meant talk of Afrezza and SOC outside of our board and outside of MNKD employees. If the medical community starts talking about it--which might start showing up in social media and on-line documentation, then... Well, we just had another story here on proboards of a patient going to a doctor who refused to prescribe Afrezza and cited potential safety issues. So, yes, when we start getting stories of people going to their regular endo and hearing that Afrezza is the standard of care in their practice (or lots of docs tweeting about primarily prescribing Afrezza)... wow, that will be big. Think it's a LONG way off, however. So far this SOC talk is limited ONLY to management and shareholders. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 6, 2018 14:29:49 GMT -5
dreamboatcruise - I agree. I meant talk of Afrezza and SOC outside of our board and outside of MNKD employees. If the medical community starts talking about it--which might start showing up in social media and on-line documentation, then... Well, we just had another story here on proboards of a patient going to a doctor who refused to prescribe Afrezza and cited potential safety issues. So, yes, when we start getting stories of people going to their regular endo and hearing that Afrezza is the standard of care in their practice (or lots of docs tweeting about primarily prescribing Afrezza)... wow, that will be big. Think it's a LONG way off, however. So far this SOC talk is limited ONLY to management and shareholders. SOC designation is about 7 years away. There is no way MNKD is going to get that without more trials and MORE DATA. There's a huge hurdle to get that classification. |
|
|
|
Post by drman7 on Jun 6, 2018 14:45:36 GMT -5
I have no issue with it. More skin in the game. Normally purchased shares at a slight discount but not sure on this plan. It might just be at market value. But why not have it? Let them buy shares with Payroll dollars is just like saving in a 401K. Also a GREAT SIGNAL to the street that the company is confident about being around in the future. I agree. Also, ESPP is part of most employment packages in corporate America when hiring, especially if company is a public one. On a side note I am not sure if Mannkind matches on employees 401K contributions, because if they don't, then this is a way to offset that. |
|
|
|
Post by drman7 on Jun 6, 2018 14:48:19 GMT -5
Perhaps it is as simple as MNKD making a move to look and smell more like a real corporate entity. If I were an employee, I would like the option to buy in house. My brief stints with large corporations have had stock purchase plans but with a discount. If there is no discount, there isn't really an advantage to the employee. I believe one of the plans I had many years ago was something like once a quarter there was a purchase date. We got 15% discount to the lower the average over the past quarter or the market price on the purchase date. That was a sweet deal because one could always turn around and sell at a profit. Though I might be conflating terms from 2 plans I've participated in long ago. Perhaps to offer a discount it must be approved by shareholders. I was in a ESPP plan with Lucent Technologies and basically you do get a discount but there is a vesting period for retention purposes  |
|
|
|
Post by bill on Jun 7, 2018 9:44:37 GMT -5
dreamboatcruise - I agree. I meant talk of Afrezza and SOC outside of our board and outside of MNKD employees. If the medical community starts talking about it--which might start showing up in social media and on-line documentation, then... Well, we just had another story here on proboards of a patient going to a doctor who refused to prescribe Afrezza and cited potential safety issues. So, yes, when we start getting stories of people going to their regular endo and hearing that Afrezza is the standard of care in their practice (or lots of docs tweeting about primarily prescribing Afrezza)... wow, that will be big. Think it's a LONG way off, however. So far this SOC talk is limited ONLY to management and shareholders. - I had a thought about how the use of Afrezza for T2's might compare to dental care. Back in the day, if you had tooth decay, they'd prescribe palliative measures until that didn't work, then pull the tooth and replace it with a wooden implant until that didn't work. Then someone invented fillings, root canals, and dentures to restore normal function. Seems to me like the standard of care today for T2's is purely palliative. Doesn't do a darn thing about the underlying problem which then gets worse and causes even bigger problems. Maybe that's why Dr. K used the phrase barbaric! "Afrezza, doing for diabetes what fillings do for teeth?"  |
|
|
|
Post by me on Jun 7, 2018 10:31:46 GMT -5
why does that show confidence? What would happen if the company goes bk anyway? Absolutly not saying that's what will happen but i dont see the link between the two things. Some perception - mostly reality... imo, most would view it as a good sign. Here’s an excerpt about these type programs. Also a link to the entire article, if interested. ”Being part of an ESOP company can provide unique rewards for employees. Participants in the plan can receive significant retirement benefits at no monetary cost to them. Research shows ESOP companies are more productive, faster growing, more profitable and have lower turnover — benefits that accrue to all stakeholders including the retirement accounts of the employee-owners. In addition, an ESOP is a great way to enhance the company’s ability to recruit and retain top talent. Effective and ongoing employee communications to encourage employees to think and act like owners is necessary in order to generate these benefits.” www.di.net/articles/employee-stock-ownership-plans-the-pros-and-cons/The MNKD program IS NOT an ESOP. An ESOP is a completely different vehicle whereby the original owner(s) of a company sell their shares to employees. The company is then employee-owned (and therefore, private and not publicly-traded). The MNKD program is simply a mechanism whereby employees can purchase shares directly (and evidently not at a discount). |
|
